Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bupropion - Biovail Corporation

Next Previous
Drug Profile

Bupropion - Biovail Corporation

Alternative Names: 323U66; Amfebutamone; Amfebutamone SR; Aplenzin; Bupropion HCL SR; Bupropion hydrobromide; Bupropion hydrochloride; Bupropion hydrochloride SR; Bupropion XL; BVF 033; Elontril; Quomem; Wellbutrin; Wellbutrin SR; Wellbutrin XL; Wellbutrin XR; Zyban

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biovail Corporation
  • Developer Bausch Health Companies; GSK
  • Class Antidepressants; Obesity therapies; Propiophenones; Small molecules; Smoking cessation therapies
  • Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Major depressive disorder; Seasonal affective disorder; Smoking withdrawal
  • No development reported Obesity; Post-traumatic stress disorders; Social phobia

Most Recent Events

  • 24 May 2021 Boehringer Ingelheim plans a phase I pharmacokinetic trial in healthy volunteers (PO) in June 2021 (NCT04899674)
  • 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
  • 17 Mar 2017 GlaxoSmithKline completes a phase III trial in Major Depressive Disorder in China (NCT02191397)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top